{"id":"W2896936188","doi":"10.1016/j.ejca.2018.09.020","title":"Letter comments on a published article in the New England Journal of Medicine","year":2018,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Seattle Genetics; Takeda Pharmaceuticals U.S.A.","keywords":"Brentuximab vedotin; ABVD; Dacarbazine; Vinblastine; Medicine; Bleomycin; Oncology; Internal medicine; Antibody-drug conjugate; Hodgkin lymphoma; Lymphoma; Vincristine; Chemotherapy; Immunology; Antibody; Monoclonal antibody; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001785974,0.0002344709,0.0006481131,0.0003069171,0.00003064556,0.0000655071,0.0004029197,0.00007326825,0.0008883339],"category_scores_gemma":[0.0002644717,0.0001097796,0.0002126821,0.0001673344,0.0001141725,0.0001169687,0.00002610908,0.001338378,0.00002621714],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002614265,"about_ca_system_score_gemma":0.0002459876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003311647,"about_ca_topic_score_gemma":0.000008630772,"domain_scores_codex":[0.996873,0.0006966688,0.0009947951,0.0001281993,0.001057934,0.0002494488],"domain_scores_gemma":[0.9977595,0.0002314175,0.001198145,0.0002955823,0.0003769805,0.0001383318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004393837,0.0001509277,0.004148782,0.00002683138,0.0003828929,0.01261003,0.001730561,0.000001950665,0.00003277639,0.000001274142,0.9585797,0.02189486],"study_design_scores_gemma":[0.01885429,0.002866045,0.04413357,0.002018908,0.0004686958,0.001267115,0.0000361057,6.52448e-7,0.000104174,0.0000289493,0.9301367,0.00008480588],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.03394204,0.002595253,0.000009254844,0.9572279,0.001423805,0.0001392206,0.000004163988,0.000002129615,0.004656182],"genre_scores_gemma":[0.1151725,0.0005740605,0.00006932847,0.8347786,0.04858875,0.000001180404,0.000004432745,0.00004344152,0.0007677531],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.1224494,"threshold_uncertainty_score":0.9726633,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02863467266914706,"score_gpt":0.2940017579017004,"score_spread":0.2653670852325533,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}